Conspicuity of prostate cancer on multiparametric magnetic resonance imaging: A cross‐disciplinary translational hypothesis

  title={Conspicuity of prostate cancer on multiparametric magnetic resonance imaging: A cross‐disciplinary translational hypothesis},
  author={J. Norris and B. Simpson and A. Freeman and A. Kirkham and H. Whitaker and M. Emberton},
  journal={The FASEB Journal},
  pages={14150 - 14159}
Pre‐biopsy multiparametric magnetic resonance imaging (mpMRI) has transformed the risk stratification and diagnostic approach for suspected prostate cancer. The majority of clinically significant prostate cancers are visible on pre‐biopsy mpMRI, however, there are a subset of significant tumors that are not detected by mpMRI. The radiobiological mechanisms underpinning mpMRI‐visibility and invisibility of these cancers remain uncertain. Emerging evidence suggests that mpMRI‐visible tumors are… Expand
1 Citations
Does modern active surveillance offer an opportunity for new therapeutic strategies in early prostate cancer?
National and international guidelines endorse AS as the preferred method of managing men with low-risk disease and as an option for selected men with intermediate-risk features (1). For this latterExpand


Molecular Hallmarks of Multiparametric Magnetic Resonance Imaging Visibility in Prostate Cancer.
A confluence of aggressive molecular and microenvironmental phenomena underlie mpMRI visibility of localized prostate cancer, and a snoRNA signature synergized with nimbosus hallmarks to discriminate visible from invisible tumors. Expand
Genomic Evaluation of Multiparametric Magnetic Resonance Imaging-visible and -nonvisible Lesions in Clinically Localised Prostate Cancer
This study shows that tumour heterogeneity within prostate tumours visible on multiparametric magnetic resonance imaging (mpMRI) can lead to misclassification of patients if only one core is used for genomic analysis, and there is inconsistency in individual genomics when genomic classifiers are applied. Expand
Genetic correlates of prostate cancer visibility (and invisibility) on multiparametric magnetic resonance imaging: it's time to take stock
This finding is important, given that in PROMIS, no men with overall Gleason score 4 + 3 had negative pre-biopsy mpMRI, indicating that actually mpMRI may identify all truly significant cancer (if SPCG-4 is used to guide the authors' threshold). Expand
Genetic landscape of prostate cancer conspicuity on multiparametric MRI: a protocol for a systematic review and bioinformatic analysis
A protocol for the first systematic review and novel bioinformatic analysis of the genomic basis of prostate cancer conspicuity on multiparametric MRI is described, to ensure methodological rigour. Expand
Prostate cancer visibility on multiparametric magnetic resonance imaging: high Gleason grade and increased tumour volume are not the only important histopathological features
Histopathological features (beyond grade and volume) associated with tumour conspicuity on mpMRI are explored, which mean small, low-grade cancers can be avoided, whilst high-risk tumours can be detected. Expand
Detection of Individual Prostate Cancer Foci via Multiparametric Magnetic Resonance Imaging.
Magnetic resonance imaging of the prostate before surgical removal for prostate cancer finds less than half of all individual prostate cancer tumors and less than two-thirds of clinically significant CaP foci. Expand
What Type of Prostate Cancer Is Systematically Overlooked by Multiparametric Magnetic Resonance Imaging? An Analysis from the PROMIS Cohort
Prostate cancers that are undetected by magnetic resonance imaging (MRI) are smaller and less aggressive than those that are detected, and none of the most aggressive cancers are overlooked by MRI. Expand
Histological differences in cancer cells, stroma, and luminal spaces strongly correlate with in vivo MRI-detectability of prostate cancer
Investigation of plausible histopathological factors that affect the detectability of prostate cancers on multiparametric magnetic resonance imaging found changes in cancer cells, stroma, and luminal spaces could be considered one of the best predictors to clinical, in vivo MRI-detectable of prostate cancer. Expand
Correlation between genomic index lesions and mpMRI and 68Ga-PSMA-PET/CT imaging features in primary prostate cancer
Imaging features of mpMRI and 68Ga-PSMA-PET/CT can guide to the genomically most aggressive lesion of a PCa, and radiogenomics may help to better differentiate between indolent and aggressive PCa in the future. Expand
Multiparametric Magnetic Resonance Imaging Features Identify Aggressive Prostate Cancer at the Phenotypic and Transcriptomic Level
The PIRADS score is associated with adverse pathology results, increased metastatic risk and differential genomic pathway activation, according to retrospectively analyzed the records of 206 patients who underwent radical prostatectomy between 2013 and 2017. Expand